AHA blog: PhRMA report misleads on drug costs
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs for Americans, writes AHA Executive Vice President Tom Nickels.
Related News Articles
Perspective
The widespread belief that we have completely turned the corner in our fight against COVID-19 does not apply equally to all parts of the country. In many…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
The Health Resources and Services Administration’s Small Rural Hospital Improvement Program yesterday provided states $398 million from the American…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).
“America’s hospitals and health systems are…